Strategic update

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Strategic update

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, notes the recent fall in the Company's share price.

As previously announced on 10 February 2025, the Company has been exploring strategic partnerships and business synergies to build its critical mass, whilst in parallel seeking additional financing to extend its limited cash runway in light of the slower than expected conversion of certain contracts.

The Company has appointed Alvarez & Marsal to undertake a targeted outreach to potential partners and investors for the Company's trading subsidiary. The Company is also in active discussions with existing investors and with brokers regarding a fundraising with the intention of raising sufficient capital to extend its cash runway beyond April 2025.

The Company remains confident in its longer-term prospects and reiterates the outlook set out in its results announcement of 10 February 2025. Oncimmune entered this current financial year having achieved growth at an unprecedented rate with some positive indicators for this growth continuing into 2025 and beyond. A material proportion of contracted revenue forecast for the current financial year remains to be collected as cash, and the pipeline of work from existing customers may grow to reflect follow-on projects. There are eleven further live projects under discussion with a potential value of over £1.8m and a number of significant strategic collaborations and transformative contracts. Whilst there is no certainty as to value and timing of such contracts, they would, if they proceed, materially impact Oncimmune's financial performance.

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information:

Contact Alvarez &Marsal : [email protected]

[email protected]

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (Corporate Broking)

+44 (0) 20 7220 0500

Zeus (Joint Broker)

Dominic King

+44 (0)20 3829 5000

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com